1. World Health Organization. Ageing and health. 2018. http://www.who.int/news-room/fact-sheets/detail/ageing-and-health. Accessed 20-07-18 .
2. Fabbri E, Zoli M, Gonzalez-Freire M, Salive ME, Studenski SA, Ferrucci L. Aging and Multimorbidity: New Tasks, Priorities, and Frontiers for Integrated Gerontological and Clinical Research. J Am Med Dir Assoc . 2015;16(8):640-7.
3. World Health Organization. Global health and ageing. 2011. https://www.who.int/ageing/publications/global_health.pdf?ua=1
4. Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17(6):571-84.
5. Pont LG, McLachlan AJ. Drug Metabolism in Older People—A Key Consideration in Achieving Optimal Outcomes With Medicines. The Journals of Gerontology: Series A. 2011;67A(2):175-80.
6. Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185-96.
7. Fried TR, O’Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health Outcomes Associated with Polypharmacy in Community-Dwelling Older Adults: A Systematic Review. J Am Geriatr Soc. 2014;62(12):2261-72.
8. Palmer K, Villani ER, Vetrano DL, Cherubini A, Cruz-Jentoft AJ, Curtin D et al. Association of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta-analysis.Eur Geriatr Med . 2019;10(1):9-36.
9. Medication Safety in Polypharmacy. Geneva: World Health Organization; 2019 (WHO/UHC/SDS/2019.11). Licence: CC BY-NC-SA 3.0 IGO
10. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.
11. Khanna S, Rolls DA, Boyle J, Xie Y, Jayasena R, Hibbert M, Georgeff M. A risk stratification tool for hospitalisation in Australia using primary care data. Sci Rep. 2019;9(1):5011.
12. Wallace E, Stuart E, Vaughan N, Bennett K, Fahey T, Smith SM. Risk prediction models to predict emergency hospital admission in community-dwelling adults: a systematic review. Med Care. 2014;52(8):751-65.
13. Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging. 2014;9:2079-86.
14. Hartikainen S, Lonnroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci 2007;62(10):1172-81.
15. Zia A, Kamaruzzaman SB, Tan MP. Polypharmacy and falls in older people: Balancing evidence-based medicine against falls risk. Postgrad Med. 2015;127(3):330-7.
16. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol. 2014;78(4):738-47.
17. Pharmaceutical Society of Australia 2019. Medicine Safety: Take Care. Canberra: PSA.
18. Australian Commission on Safety and Quality in Health Care. Continuity of medication management. 2019. https://www.safetyandquality.gov.au/standards/nsqhs-standards/medication-safety-standard/continuity-medication-management. Accessed 24-03-21
19. Shakib S, Dundon BK, Maddison J, Thomas J, Stanners M, Caughey GE et al. Effect of a Multidisciplinary Outpatient Model of Care on Health Outcomes in Older Patients with Multimorbidity: A Retrospective Case Control Study. PloS one. 2016;11(8):e0161382.
20. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. Tools for Assessment of the Appropriateness of Prescribing and Association with Patient-Related Outcomes: A Systematic Review.Drugs Aging . 2018;35(1):43-60.
21. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. Rationalisation of polypharmacy in practice: a survey of physicians and pharmacists.J Pharm Pract Res . 2019.
22. Australian Medicines Handbook Pty Ltd. Australian Medicines Handbook. 2019. https://amhonline.amh.net.au/auth. 2019. Accessed 24-03-21
23. SA Department of Health and Ageing Safety and Quality Unit. High risk medicines. 2017. https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/clinical+resources/clinical+topics/medicines+and+drugs/high+risk+medicines. Accessed 06-11-18 .
24. American Geriatrics Society. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227-46.
25. Colagiuri S DS, Girgis S, Colagiuri R. Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes Canberra 2009.
26. Lung Foundation Australia. Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2018.
27. Heart Foundation. Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2018.
28. Steinman MA. Polypharmacy-Time to Get Beyond Numbers.JAMA Intern Med . 2016;176(4):482-3.
29. Fried TR, Mecca MC. Medication Appropriateness in Vulnerable Older Adults: Healthy Skepticism of Appropriate Polypharmacy.J Am Geriatr Soc . 2019;67(6):1123-7.
30. Sirois C, Tannenbaum C, Gagnon M-E, Milhomme D, Émond V. Monitoring polypharmacy at the population level entails complex decisions: results of a survey of experts in geriatrics and pharmacotherapy. Drugs & Therapy Perspectives. 2016;32(6):257-64.
31. Parekh N, Ali K, Davies JG, Stevenson JM, Banya W, Nyangoma S et al. Medication-related harm in older adults following hospital discharge: development and validation of a prediction tool.BMJ Qual Saf 2020;29(2):142-153.
32. Sixth Community Pharmacy Agreement. Home Medicines Review. http://6cpa.com.au/medication-management-programs/home-medicines-review/. Accessed 02-10-19 .
33. Burt J, Elmore N, Campbell SM, Rodgers S, Avery AJ, Payne RA. Developing a measure of polypharmacy appropriateness in primary care: systematic review and expert consensus study. BMC Med. 2018;16(1):91.